Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2023-04-19 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
营业收入扣除情况表专项核查报告
Audit Report / Information Classification · 95% confidence The document is a specialized verification report issued by an accounting firm (致同会计师事务所) regarding the company's 2022 annual revenue deduction statement. It references the 2022 fiscal year and includes detailed financial data about revenue deductions, net profit, and related explanations. The report is not a full annual report but a standalone audit-related verification focused on a specific financial aspect (revenue deductions). It includes audit procedures and an auditor's conclusion, indicating it is an audit report or information related to accounting verification. The document length is under 5,000 characters and contains substantive financial data and audit conclusions, so it is not merely an announcement or certification. Therefore, the best fitting category is Audit Report / Information (AR). FY 2022
2023-04-19 Chinese
2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "赛隆药业集团股份有限公司2023 年第一季度报告" which translates to "Sailong Pharmaceutical Group Co., Ltd. 2023 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and shareholder information for the first quarter of 2023. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter. It also mentions that the report is unaudited. The length of the document (10,787 characters) and the detailed financial content confirm it is a substantive financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-04-19 Chinese
2022年年度报告
Annual Report Classification · 100% confidence The document is titled "赛隆药业集团股份有限公司2022 年年度报告全文" which translates to "Sailong Pharmaceutical Group Co., Ltd. 2022 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data for the year 2022, management discussion and analysis, business description, product details, and financial performance metrics. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes signed financial statements and audit reports as referenced in the table of contents and the preface. The presence of detailed financial figures, management analysis, and company operations confirms this is the full Annual Report for the fiscal year 2022. Therefore, the correct classification is Annual Report (10-K). FY 2022
2023-04-19 Chinese
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2022 from a specific independent director of the company. It details the director's attendance at board and shareholder meetings, opinions on various company matters, committee participation, and efforts to protect investor rights. The content focuses on the director's duties, opinions, and activities rather than financial results or audit opinions alone. It is a report on the independent director's performance and responsibilities rather than a full audit report or annual report. This type of document fits best under Board/Management Information (MANG), as it relates to management-level reporting on governance and director activities rather than financial statements or audit results.
2023-04-19 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 14th meeting of the 3rd Board of Directors of Sailong Pharmaceutical Group Co., Ltd. It includes information about the meeting date, attendance, and voting results on various agenda items such as the 2022 annual reports, financial statements, profit distribution plan, internal control report, accounting policy changes, and credit applications. The document repeatedly states that the detailed reports and announcements are published separately on the official information disclosure website (cninfo.com.cn). This document itself is not the full reports but a formal announcement of board meeting decisions and approvals, which is typical of a Board/Management Information filing. It does not contain the full financial data or the actual reports but summarizes board resolutions and references where the full reports can be found. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (2813 characters) and content confirm it is not a full annual report or financial report but a board meeting resolution announcement.
2023-04-19 Chinese
关于2022年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the asset impairment provisions for the fiscal year 2022. It details the reasons, amounts, and accounting basis for the impairment provisions, including bad debt and inventory write-downs. The document is relatively short (2118 characters) and serves as a formal disclosure of the impairment provision decision and its impact on the financial results. It does not contain full financial statements or comprehensive financial analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a specific announcement about a particular accounting event (asset impairment provision) that affects the financials. This type of document fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and disclosures that do not fit other specific categories. Therefore, the classification is RNS with high confidence.
2023-04-19 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.